secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001193125-23-188839
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia expands trofinetide rights globally; Q2 DAYBUE net sales $21-23M
-----------------------------------------------------------------------

- Acadia pays Neuren $100M upfront for ex-North American trofinetide rights and global NNZ-2591 rights in Rett/Fragile X.
- Potential milestone payments up to $405M each for trofinetide and NNZ-2591 in North America; additional milestones outside NA.
- Preliminary Q2 2023 DAYBUE net sales $21-23M; Q3 guidance $45-55M.
- NUPLAZID Q2 preliminary net sales $140-144M; full year 2023 guidance $530-545M.
- Acadia to submit NDS for trofinetide in Canada within 18 months; plans for Europe, Asia later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/d533087d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-188839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer